Epilepsy Pipeline: Insights into Novel and Emerging Pipeline Therapies, Key Pharma Players, Clinical Trials, Growth Prospects, and Treatment Landscape | DelveInsight
The Epilepsy Pipeline landscape is evolving with increased insight into biological pathways and mechanisms underlying Epilepsy, leading towards more targeted therapies.
DelveInsight’s ‘Epilepsy Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies under different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Epilepsy pipeline domain.
Some of the essential takeaways from the Epilepsy Pipeline report:
DelveInsight’s Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
Key Epilepsy pipeline therapies such as OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others are under investigation in different phases of clinical trials.
In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA’s Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.
In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.
Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Emerging Therapies and Forecast
The Epilepsy pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Epilepsy products, comprehensive assessment of driving and restraining factors, and opportunities as well as risks in the Epilepsy pipeline landscape.
Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behavior. The primary cause of Epilepsy is not clear, but it is noted that any change in the nerve cells, neurons, and the brain resulting in abnormal signals can be the possible reason.
The most common symptom of Epilepsy includes seizures; however, additional symptoms like convulsion without fever, low consciousness, less awareness, loss of taste, smell, sight, hearing, etc., can also be present.
For further information about Epilepsy treatment and pipeline therapies, visit @ Epilepsy Pipeline Assessment
Epilepsy Pipeline Drugs
Drug Company Phase MoA RoA
OPC-214870 Otsuka Pharmaceutical Co. Ltd Phase I Antiepileptic Oral
CT-010 Cerebral Therapeutics LLC Phase II 4-aminobutyrate transaminase inhibitors Intraventricular
Ganaxolone Marinus Pharmaceuticals Phase III GABA A receptor agonists Intravenous
XEN496 Xenon Pharmaceuticals Phase III KCNQ potassium channel agonists Oral
Vatiquinone PTC Therapeutics Phase II/III NQO1 modulators Oral
E-2730 Eisai Phase II Synaptic transmission modulators Oral
NBI 827104 Neurocrine Biosciences Phase II T type calcium channel antagonists Oral
Request for Sample to know more @ Epilepsy Pipeline Analysis and Trends
Epilepsy Therapeutics Assessment
The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
By Route of Administration
By Molecule Type
Stem cell therapy
By Mechanism of Action
4-aminobutyrate transaminase inhibitors
GABA A receptor agonists
KCNQ potassium channel agonists
Serotonin receptor agonists
T type calcium channel antagonists
GABA A receptor
KCNQ potassium channel
T type calcium channel
Scope of the Epilepsy Pipeline Report
Major Players: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.
Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ Epilepsy Pipeline Emerging Novel Therapies
Table of Contents
2 Executive Summary
3 Epilepsy: Overview
4 Epilepsy – Analytical Perspective In-depth Commercial Assessment
5 Pipeline Therapeutics
6 Late Stage Products (Phase III)
7 Late Stage Products (Phase II/III)
8 Mid Stage Products (Phase II)
9 Early Stage Products (Phase I)
10 Therapeutic Assessment
11 Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Epilepsy Key Companies
14 Epilepsy Key Products
15 Epilepsy- Unmet Needs
16 Epilepsy- Market Drivers and Barriers
17 Epilepsy- Future Perspectives and Conclusion
18 Epilepsy Analyst Views
20 About DelveInsight
Get Epilepsy customized report @ Epilepsy Emerging Therapies
Track candidate’s clinical development journey here @ Profiling and Comparative Therapeutic Assessment
Partial Epilepsy Pipeline
“Partial Epilepsy Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario including mechanism of action of the drug, clinical studies, Partial Epilepsy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details as well as growth prospects across the Partial Epilepsy market.
DelveInsight’s ‘Epilepsy – Market Insights, Epidemiology and Market Forecast– 2030’ report offers rich insights into epidemiology, current and marketed treatments, growth prospects, and key companies including Neurelis, Biocodex, Aquestive Therapeutics, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Eisai Pharmaceuticals, Janssen Pharmaceuticals, Eisai, Zogenix, UCB, SK Life Science, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Supernus Pharmaceuticals, Lundbeck, Pfizer, and many others.
Drug-Resistant Epilepsy Epidemiology
DelveInsight’s ‘Drug Resistant Epilepsy – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Drug-Resistant Epilepsy epidemiology in the 7MM.
Hepatic Colorectal Metastasis Pipeline
“Hepatic – Colorectal Metastasis Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development pipeline scenario and growth prospects across the Hepatic – Colorectal Metastasis market.
“Bunion Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario including mechanism of action of the drug, clinical studies, Bunion collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details as well as growth prospects across the Bunion market.
Persistent Epithelial Defect Market
DelveInsight’s “Persistent Corneal Epithelial Defects (PEDs) – Market Insights, Epidemiology, and Market Forecast – 2030” report provides a detailed overview of the disease. Key companies include Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others are developing Persistent Epithelial Defect therapies.
Alzheimer’s Disease Market
DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Alzheimer’s Disease, historical and forecasted epidemiology as well as the Alzheimer’s disease market trends, current treatment practices, emerging drugs, Alzheimer’s Disease market share of the individual therapies, current and forecasted Alzheimer’s Disease market.
Huntington’s Disease Pipeline
DelveInsight’s, “Huntington’s Disease – Pipeline Insight, 2021,” report offers rich insights into epidemiology, treatments, pipeline therapies, and key companies including Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and several others.
Browse Through Our Blog Posts
Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape?
In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs.
Ever-evolving Market Dynamics of Epilepsy – a silver lining!
The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects.
21 of the most common questions about Epilepsy
The term Epilepsy isn’t new. It’s been present in the air for centuries now, however, only a few are aware that it is one of the most common neurological diseases in the world.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.